Rezolute, Inc. (RZLT)
| Market Cap | 103.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.13M |
| Shares Out | 33.58M |
| EPS (ttm) | -3.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,761 |
| Open | 2.87 |
| Previous Close | 2.93 |
| Day's Range | 2.87 - 3.29 |
| 52-Week Range | 2.26 - 11.31 |
| Beta | 2.85 |
| Analysts | Buy |
| Price Target | 14.03 (+357.0%) |
| Earnings Date | Sep 13, 2022 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for RZLT stock is "Buy." The 12-month stock price forecast is 14.03, which is an increase of 357.00% from the latest price.
News
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to d...
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Announced a $130 million registered direct offering and concurrent private placement
Rezolute to Host Corporate Update Call on May 4, 2022
Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET
Rezolute, Inc. Announces Closing of Registered Direct Offering
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to di...
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At...
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to di...
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET
Rezolute Joins the Rare Disease Company Coalition
Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving therap...
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated wi...
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent ...
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Dire...
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for me...
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of C...
Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated w...
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsul...
Tracking to Announce Top line data in Q1 2022
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to c...
Rezolute Added to Russell Microcap® Index
REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to ch...
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated wit...
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalan...
Rezolute to Participate in Upcoming Investor Conferences in March
REDWOOD CITY, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced that Nevan Charles Elam, the Company's CEO and Founder, will be presenting at the following upcomi...
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), today announced its financial results for the quarter ended December 31, 2020.
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Dia...
RZ402 is a plasma kallikrein inhibitor being investigated as a potential once-daily, oral therapy for DME